Clinical Data Shows One-Third of Infants Outgrow Peanut Allergies by Age One

For decades, a positive skin prick or blood test for a suspected peanut allergy delivered a definitive verdict to parents, initiating a childhood defined by strict dietary avoidance and constant vigilance. Unlike many diagnostic screens that confirm a disease, these initial allergy tests only measure immune sensitization, leaving a gap between a positive result and a true clinical reaction.[1]

New clinical data from a nationwide Australian initiative demonstrates exactly how wide that diagnostic gap has become. Researchers have found that more than a third of infants carrying a suspected peanut allergy diagnosis may not actually be allergic when exposed to the food in a controlled clinical setting.[2][4]

The findings emerge from the ADAPT Peanut Oral Immunotherapy Program, a world-first model of care integrated into mainstream pediatric hospitals rather than isolated clinical trials. Led by the Murdoch Children’s Research Institute and the National Allergy Centre of Excellence, the program is reshaping how health systems approach early childhood food allergies.[5][6]

Australia reports some of the highest rates of childhood food allergies globally, with peanut allergies affecting approximately one in 30 children by their first birthday. This high prevalence has strained pediatric allergy clinics and left thousands of families navigating the intense anxiety of managing a potentially life-threatening condition.[2][5]

The Diagnostic Gap in Allergy Testing

To evaluate the true scale of the allergy burden, the ADAPT program assessed 1,275 infants under 18 months of age across 10 pediatric public hospitals in five Australian states. These infants had all presented with a recent suspected reaction to peanuts and a subsequent positive allergy test.[2][4]

Rather than accepting the initial tests as conclusive, clinical teams guided 778 of these infants through a supervised oral food challenge. This gold-standard diagnostic tool involves feeding the child precisely measured, increasing doses of peanut protein under strict medical observation to monitor for any adverse immune response.[5][6]

The results of these challenges revealed that 35 percent of the tested infants did not mount an allergic reaction. Because they tolerated the peanut doses without incident, these children were officially cleared, allowing clinicians to safely remove their peanut allergy diagnosis entirely.[2][3]

Dr. Tim Brettig, the ADAPT Medical Lead and a senior research clinician at the Murdoch Children’s Research Institute, emphasized that the data underscores the necessity of confirming an allergy before committing a family to years of intervention. He noted that relying solely on clinical history and initial sensitization tests frequently results in an unnecessary allergy label.[2][4]

Clearing the Allergy Label

"We found more than one third of infants who were suspected to have peanut allergy based on their history and initial tests no longer reacted when they underwent a supervised food challenge," Brettig stated. Identifying these children early spares them from the significant burden of lifelong peanut avoidance.[2]

For the families of the cleared infants, the removal of the diagnosis eliminates the need to scrutinize every ingredient label, carry epinephrine auto-injectors, and worry about cross-contamination at social events. Clinicians advise these parents to regularly incorporate age-appropriate peanut products, such as smooth peanut butter, into their child's diet to maintain the natural tolerance.[1][5]

AI

The high clearance rate highlights a known limitation of standard allergy diagnostics. Skin prick tests and specific IgE blood tests detect the presence of antibodies primed to recognize peanut proteins, but they cannot definitively predict whether the immune system will trigger a systemic reaction upon actual ingestion.[1][6]

While the oral food challenge successfully cleared a third of the cohort, it also provided critical, definitive confirmation for the 65 percent of infants who did experience an allergic reaction during the clinical test.[2][4]

Managing Severe Reactions Safely

Conducting these challenges in a specialized hospital environment proved essential for patient safety. According to the study data, 12 percent of the infants who reacted during the challenge experienced anaphylaxis, a severe and potentially life-threatening systemic response.[2]

Because the challenges were supervised by specialized pediatric allergy teams, every allergic episode was rapidly identified and safely managed with immediate medical intervention. This controlled environment ensures that infants are not exposed to their first severe reaction at home or in a daycare setting.[5][6]

For the infants whose peanut allergy was definitively confirmed by the challenge, the ADAPT program immediately provided a structured pathway forward. Rather than sending families home with instructions to simply avoid peanuts, the clinical teams transitioned the reacting infants into an active treatment protocol.[2][5]

The data shows that 97.5 percent of the infants who reacted during their oral food challenge successfully initiated peanut oral immunotherapy. The starting dose for the immunotherapy was precisely calibrated based on the individual threshold established during their clinical challenge.[2][4]

Retraining the Immune System

Oral immunotherapy represents a paradigm shift in allergy management, moving away from strict avoidance toward active immune desensitization. The treatment involves feeding the allergic child a tiny, precisely measured dose of peanut powder every day, mixed into their regular food.[5][6]

Over a period of two years, the clinical teams carefully guide parents to gradually increase the daily peanut dose. This slow, sustained exposure is designed to retrain the infant's developing immune system, teaching it to tolerate the peanut protein without launching a defensive attack.[5][6]

While oral immunotherapy is not considered a definitive cure, successful desensitization significantly raises the threshold amount of peanut required to trigger a reaction. This provides a crucial safety net against accidental exposures, transforming a potentially fatal encounter with trace amounts of peanut into a harmless event.[1][5]

In the most successful cases, early intervention can lead to clinical remission, allowing the child to eventually consume peanuts freely without requiring ongoing daily maintenance doses. The program's focus on infants under 18 months capitalizes on the plasticity of the early immune system.[1][6]

Shifting the Standard of Care

Professor Kirsten Perrett, Director of the National Allergy Centre of Excellence and the ADAPT Program Lead, noted that the findings carry profound implications for how pediatric food allergies are diagnosed and managed on a national scale. The data proves that clinical history and standard testing are simply not enough to accurately diagnose peanut allergy in many cases.[2][4]

Perrett advocates that a supervised oral food challenge should become a routine, mandatory step to confirm a diagnosis before any infant is enrolled in an oral immunotherapy program. This ensures that intensive medical resources are directed only toward children who genuinely require the intervention.[2][5]

AI

"With peanut allergy one of the most common childhood food allergies, it's particularly important that we have an accurate diagnosis when a baby first shows signs of a possible peanut allergy," Perrett explained. Accurate initial diagnoses prevent the healthcare system from being overwhelmed by false positives.[2]

The integration of the ADAPT program into 10 public hospitals demonstrates that complex allergy treatments can be successfully scaled outside of isolated research environments. By standardizing the diagnostic and treatment protocols, the initiative provides equitable access to cutting-edge care.[5][6]

Scaling Pediatric Allergy Treatment

Public health officials are closely monitoring the program's outcomes, as the model could eventually be adapted for other common childhood allergens, such as egg and dairy. Establishing a reliable pathway from diagnosis to desensitization offers a blueprint for modernizing allergy care globally.[1][6]

Ultimately, the Australian clinical data reinforces the value of definitive testing. By safely clearing one-third of suspected cases and actively treating the rest, the program replaces the chronic anxiety of an allergy label with a clear, actionable path forward for thousands of families.[2][4]